OncoMed Pharmaceuticals, Inc. Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)

Published: Aug 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., Aug. 22, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,507,442 to OncoMed for methods of treating cancer with its antibody vantictumab (OMP-18R5). Vantictumab targets and inhibits the Wnt pathway, which is believed to be an important CSC pathway. The patent expires in 2029.

Help employers find you! Check out all the jobs and post your resume.

Back to news